Inhibition of soluble epoxide hydrolase prevents renal interstitial fibrosis and inflammation

American Journal of Physiology - Renal Physiology

Volumn 307, Issue 8, 2014, Pages F971-F980

  Kim, Jinu ^a,b,c   Imig, John D ^d   Yang, Jun ^e   Hammock, Bruce D ^c   Padanilam, Babu J ^a,f  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Jeju National University School of Medicine   (South Korea)

^c Jeju National University   (South Korea)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Chronic kidney disease; PPAR isoforms; Soluble epoxide hydrolase; Tubulointerstitial fibrosis; Unilateral ureteral obstruction

Indexed keywords

CHEMOTACTIC FACTOR; COLLAGEN; CYTOKINE; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; FIBRONECTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SMAD3 PROTEIN; SOLUBLE EPOXIDE HYDROLASE; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 4-(4-(3-ADAMANTAN-1-YLUREIDO)CYCLOHEXYLOXY)BENZOIC ACID; BENZOIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME DEFICIENCY; ENZYME INHIBITION; FIBROGENESIS; FIBROSING ALVEOLITIS; ISOMER; KIDNEY FAILURE; KIDNEY FIBROSIS; MACROPHAGE; MALE; MOLECULAR MECHANICS; MOUSE; MYOFIBROBLAST; NEPHRITIS; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RENAL PROTECTION; SIGNAL TRANSDUCTION; UNILATERAL URETERAL OBSTRUCTION; URETER OBSTRUCTION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; C57BL MOUSE; DRUG EFFECTS; FIBROSIS; KIDNEY; KIDNEY DISEASES; METABOLISM; NECROSIS; PATHOLOGY;

ANIMALS; APOPTOSIS; BENZOATES; EPOXIDE HYDROLASES; FIBROSIS; KIDNEY; KIDNEY DISEASES; MALE; MICE, INBRED C57BL; NECROSIS; NEPHRITIS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; UREA; URETERAL OBSTRUCTION;

EID: 84908061327     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00256.2014     Document Type: Article

References (48)

1. Bakris G, Vassalotti J, Ritz E, Wanner C, Stergiou G, Molitch M, Nesto R, Kaysen GA, Sowers JR. National Kidney Foundation consen-sus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney Int 78: 726-736, 2010.
2. Basile DP, Fredrich K, Chelladurai B, Leonard EC, Parrish AR. Renal ischemia reperfusion inhibits VEGF expression and induces ADAMTS-1, a novel VEGF inhibitor. Am J Physiol Renal Physiol 294: F928-F936, 2008.
3. Boor P, Ostendorf T, Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 6: 643-656, 2010.
4. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Sup-pression of experimental glomerulonephritis by antiserum against trans-forming growth factor beta 1. Nature 346: 371-374, 1990.
5. Borges FT, Melo SA, Ozdemir BC, Kato N, Revuelta I, Miller CA, Gattone VH IInd, LeBleu VS, Kalluri R. TGF-1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regener-ative responses and fibrosis. J Am Soc Nephrol 24: 385-392, 2013.
6. Bottinger EP. TGF-in renal injury and disease. Semin Nephrol 27: 309-320, 2007.
7. Campanholle G, Ligresti G, Gharib SA, Duffield JS. Cellular mecha-nisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis. Am J Physiol Cell Physiol 304: C591-C603, 2013.
8. Chen JK, Capdevila J, Harris RC. Cytochrome p450 epoxygenase metabolism of arachidonic acid inhibits apoptosis. Mol Cell Biol 21: 6322-6331, 2001.
9. Diano S, Liu ZW, Jeong JK, Dietrich MO, Ruan HB, Kim E, Suyama S, Kelly K, Gyengesi E, Arbiser JL, Belsham DD, Sarruf DA, Schwartz MW, Bennett AM, Shanabrough M, Mobbs CV, Yang X, Gao XB, Horvath TL. Peroxisome proliferation-associated control of reactive oxygen species sets melanocortin tone and feeding in diet-induced obesity. Nat Med 17: 1121-1127, 2011.
10. Dorrance AM, Rupp N, Pollock DM, Newman JW, Hammock BD, Imig JD. An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido) dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 46: 842-848, 2005.
11. Elmarakby AA, Faulkner J, Al-Shabrawey M, Wang MH, Maddipati KR, Imig JD. Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in strep-tozotocin-induced type 1 diabetes. Am J Physiol Regul Integr Comp Physiol 301: R1307-R1317, 2011.
12. Ghosh AK, Bhattacharyya S, Wei J, Kim S, Barak Y, Mori Y, Varga J. Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional co-activator. FASEB J 23: 2968-2977, 2009.
13. Han JY, Kim YJ, Kim L, Choi SJ, Park IS, Kim JM, Chu YC, Cha DR. PPARgamma agonist and angiotensin II receptor antagonist amelio-rate renal tubulointerstitial fibrosis. J Korean Med Sci 25: 35-41, 2010.
14. Hassa PO, Covic M, Hasan S, Imhof R, Hottiger MO. The enzymatic and DNA binding activity of PARP-1 are not required for NF-B coacti-vator function. J Biol Chem 276: 45588-45597, 2001.
15. Hassa PO, Hottiger MO. A role of poly (ADP-ribose) polymerase in NF-B transcriptional activation. Biol Chem 380: 953-959, 1999.
16. Imig JD. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol 289: F496-F503, 2005.
17. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 8: 794-805, 2009.
18. Imig JD, Navar LG, Roman RJ, Reddy KK, Falck JR. Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol 7: 2364-2370, 1996.
19. Inoue T, Takenaka T, Hayashi M, Monkawa T, Yoshino J, Shimoda K, Neilson EG, Suzuki H, Okada H. Fibroblast expression of an IkappaB dominant-negative transgene attenuates renal fibrosis. J Am Soc Nephrol 21: 2047-2052, 2010.
20. Jung O, Brandes RP, Kim IH, Schweda F, Schmidt R, Hammock BD, Busse R, Fleming I. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 45: 759-765, 2005.
21. Jung O, Jansen F, Mieth A, Barbosa-Sicard E, Pliquett RU, Babelova A, Morisseau C, Hwang SH, Tsai C, Hammock BD, Schaefer L, Geisslinger G, Amann K, Brandes RP. Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease. PLos One 5: e11979, 2010.
22. Kawai T, Masaki T, Doi S, Arakawa T, Yokoyama Y, Doi T, Kohno N, Yorioka N. PPAR-agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-. Lab Invest 89: 47-58, 2008.
23. Kawai T, Masaki T, Doi S, Arakawa T, Yokoyama Y, Doi T, Kohno N, Yorioka N. PPAR-agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-. Lab Invest 89: 47-58, 2009.
24. Kim J, Long KE, Tang K, Padanilam BJ. Poly(ADP-ribose) polymerase 1 activation is required for cisplatin nephrotoxicity. Kidney Int 82: 193-203, 2012.
25. Kim J, Padanilam BJ. Loss of poly(ADP-ribose) polymerase 1 attenuates renal fibrosis and inflammation during unilateral ureteral obstruction. Am J Physiol Renal Physiol 301: F450-F459, 2011.
26. Kim J, Padanilam BJ. Renal nerves drive interstitial fibrogenesis in obstructive nephropathy. J Am Soc Nephrol 24: 229-242, 2013.
27. Kim J, Seok YM, Jung KJ, Park KM. Reactive oxygen species/oxidative stress contributes to progression of kidney fibrosis following transient ischemic injury in mice. Am J Physiol Renal Physiol 297: F461-F470, 2009.
28. Kim JC, Lee YH, Yu MK, Lee NH, Park JD, Bhattarai G, Yi HK. Anti-inflammatory mechanism of PPARgamma on LPS-induced pulp cells: role of the ROS removal activity. Arch Oral Biol 57: 392-400, 2012.
29. Kon K, Ikejima K, Hirose M, Yoshikawa M, Enomoto N, Kitamura T, Takei Y, Sato N. Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun 291: 55-61, 2002.
30. LeBleu VS, Taduri G, O’Connell J, Teng Y, Cooke VG, Woda C, Sugimoto H, Kalluri R. Origin and function of myofibroblasts in kidney fibrosis. Nat Med 19: 1047-1053, 2013.
31. Li L, Li N, Pang W, Zhang X, Hammock BD, Ai D, Zhu Y. Opposite effects of gene deficiency and pharmacological inhibition of soluble epoxide hydrolase on cardiac fibrosis. PLos One 9: e94092, 2014.
32. Liu Y, Zhang Y, Schmelzer K, Lee TS, Fang X, Zhu Y, Spector AA, Gill S, Morisseau C, Hammock BD, Shyy JYJ. The antiinflammatory effect of laminar flow: the role of PPARÎ3, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci USA 102: 16747-16752, 2005.
33. Loch D, Hoey A, Morisseau C, Hammock BO, Brown L. Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydro-lase. Cell Biochem Biophys 47: 87-98, 2007.
34. Manhiani M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, Brands MW, Hammock BD, Imig JD. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hyper-tension. Am J Physiol Renal Physiol 297: F740-F748, 2009.
35. Masaki T, Chow F, Nikolic-Paterson DJ, Atkins RC, Tesch GH. Heterogeneity of antigen expression explains controversy over glomerular macrophage accumulation in mouse glomerulonephritis. Nephrol Dial Transplant 18: 178-181, 2003.
36. McCarthy KJ, Routh RE, Shaw W, Walsh K, Welbourne TC, John-son JH. Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int 58: 2341-2350, 2000.
37. Mehal W, Imaeda A. Cell death and fibrogenesis. Semin Liver Dis 30: 226-231, 2010.
38. Ohmori Y, Fukumoto S, Hamilton TA. Two structurally distinct kappa B sequence motifs cooperatively control LPS-induced KC gene transcrip-tion in mouse macrophages. J Immunol 155: 3593-3600, 1995.
39. Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, Ruperez M, Egido J, Ruiz-Ortega M. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-independent mechanism. Circulation 111: 2509-2517, 2005.
40. Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP, Ham-mock BD. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci USA 102: 9772-9777, 2005.
41. Simpkins AN, Rudic RD, Schreihofer DA, Roy S, Manhiani M, Tsai HJ, Hammock BD, Imig JD. Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Am J Pathol 174: 2086-2095, 2009.
42. Sirish P, Li N, Liu JY, Lee KS, Hwang SH, Qiu H, Zhao C, Ma SM, Lopez JE, Hammock BD, Chiamvimonvat N. Unique mechanistic insights into the beneficial effects of soluble epoxide hydrolase inhibitors in the prevention of cardiac fibrosis. Proc Natl Acad Sci USA 110: 5618-5623, 2013.
43. Ueda A, Okuda K, Ohno S, Shirai A, Igarashi T, Matsunaga K, Fukushima J, Kawamoto S, Ishigatsubo Y, Okubo T. NF-B and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J Immunol 153: 2052-2063, 1994.
44. Venkatachalam MA, Griffin KA, Lan R, Geng H, Saikumar P, Bidani AK. Acute kidney injury: a springboard for progression in chronic kidney disease. Am J Physiol Renal Physiol 298: F1078-F1094, 2010.
45. Widmer U, Manogue KR, Cerami A, Sherry B. Genomic cloning and promoter analysis of macrophage inflammatory protein (MIP)-2, MIP-1, and MIP-1, members of the chemokine superfamily of proinflammatory cytokines. J Immunol 150: 4996-5012, 1993.
46. Xu D, Li N, He Y, Timofeyev V, Lu L, Tsai HJ, Kim IH, Tuteja D, Mateo RK, Singapuri A, Davis BB, Low R, Hammock BD, Chiamvi-monvat N. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA 103: 18733-18738, 2006.
47. Yang J, Schmelzer K, Georgi K, Hammock BD. Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Chem 81: 8085-8093, 2009.
48. Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C, Graham L, Engler MM, Hammock BD, Zeldin DC, Kroetz DL. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeico-satrienoic acids. Circ Res 87: 992-998, 2000.